{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T20:25:31Z","timestamp":1778703931633,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jpba.2019.112911","type":"journal-article","created":{"date-parts":[[2019,10,6]],"date-time":"2019-10-06T09:22:52Z","timestamp":1570353772000},"page":"112911","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Stability behaviour of antiretroviral drugs and their combinations. 11: Characterization of interaction products of zidovudine and efavirenz, and evaluation of their anti HIV-1 activity, and physiochemical and ADMET properties"],"prefix":"10.1016","volume":"178","author":[{"given":"Moolchand","family":"Kurmi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archana","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankit","family":"Balhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inder Pal","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smita","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navneet Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabha","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saranjit","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2019.112911_bib0005","series-title":"Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection, Geneva, Switzerland","author":"WHO","year":"2016"},{"key":"10.1016\/j.jpba.2019.112911_bib0010","series-title":"ART Guidelines for HIV-infected Adults and Adolescents, New Delhi, India","author":"NACO","year":"2013"},{"key":"10.1016\/j.jpba.2019.112911_bib0015","series-title":"The South African Antiretroviral Treatment Guidelines","year":"2013"},{"key":"10.1016\/j.jpba.2019.112911_bib0020","series-title":"Pharmaceutical Development, Q8(R2), Geneva, Switzerland","author":"ICH","year":"2009"},{"key":"10.1016\/j.jpba.2019.112911_bib0025","series-title":"Guidance for Industry and FDA Staff: Early Development Considerations for Innovative Combination Products, US FDA, Rockville, USA","author":"US FDA","year":"2006"},{"key":"10.1016\/j.jpba.2019.112911_bib0030","series-title":"Guideline on Submission of Documentation for Prequalification of Multi-Source (generic) Finished Pharmaceutical Products (FPPs) Used in the Treatment of HIV\/AIDS, Malaria and Tuberculosis, Geneva, Switzerland","author":"WHO","year":"2005"},{"key":"10.1016\/j.jpba.2019.112911_bib0035","first-page":"573","article-title":"Chemical interactions study of antiretroviral drugs efavirenz and lamivudine concerning the development of stable fixed-dose combination formulations for AIDS treatment","volume":"24","author":"de L. Gomes","year":"2013","journal-title":"J. Braz. Chem. Soc."},{"key":"10.1016\/j.jpba.2019.112911_bib0040","unstructured":"http:\/\/apps.who.int\/prequal\/whopar\/whoparproducts\/WHOPAR_HA408.htm. (Accessed 12 November 2016)."},{"key":"10.1016\/j.jpba.2019.112911_bib0045","unstructured":"T.C. Dahl, M.A. Hussain, R.A. Lipper, R.L. Jerzewski, M.M. Menning, R. Oliyai, T. Yang, Stable fixed-dose unitary formulations containing tenofovir, a surfactant, efavirenz and emtricitabine, WO2006135933 A2 (2006)."},{"key":"10.1016\/j.jpba.2019.112911_bib0050","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jpba.2016.03.039","article-title":"Stability behaviour of antiretroviral drugs and their combinations. 2: characterization of interaction products of lamivudine and tenofovir disoproxil fumarate by mass and NMR spectrometry","volume":"125","author":"Kurmi","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.112911_bib0055","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jpba.2016.06.021","article-title":"Stability behaviour of antiretroviral drugs and their combinations. 3: characterization of interaction products of emtricitabine and tenofovir disoproxil fumarate by mass spectrometry","volume":"128","author":"Kurmi","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.112911_bib0060","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jpba.2019.01.009","article-title":"Stability behaviour of antiretroviral drugs and their combinations. 9: identification of incompatible excipients","volume":"166","author":"Kurmi","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.112911_bib0065","doi-asserted-by":"crossref","first-page":"96117","DOI":"10.1039\/C5RA17532A","article-title":"Stability behaviour of antiretroviral drugs and their combinations. 1: characterization of tenofovir disoproxil fumarate degradation products by mass spectrometry","volume":"5","author":"Kurmi","year":"2015","journal-title":"RSC Adv."},{"key":"10.1016\/j.jpba.2019.112911_bib0070","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jpba.2016.08.022","article-title":"Stability behaviour of antiretroviral drugs and their combinations. 4: characterization of degradation products of tenofovir alafenamide fumarate and comparison of its degradation and stability behaviour with tenofovir disoproxil fumarate","volume":"131","author":"Golla","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.112911_bib0075","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jpba.2016.10.019","article-title":"Stability behaviour of antiretroviral drugs and their combinations. 5: characterization of novel degradation products of abacavir sulfate by mass and nuclear magnetic resonance spectrometry","volume":"134","author":"Kurmi","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.112911_bib0080","doi-asserted-by":"crossref","first-page":"18803","DOI":"10.1039\/C7RA00678K","article-title":"Stability behaviour of antiretroviral drugs and their combinations. 6: evidence of formation of potentially toxic degradation products of zidovudine under hydrolytic and photolytic conditions","volume":"7","author":"Kurmi","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.jpba.2019.112911_bib0085","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jpba.2017.04.034","article-title":"Stability behaviour of antiretroviral drugs and their combinations. 7: comparative degradation pathways of lamivudine and emtricitabine and explanation to their differential degradation behaviour by density functional theory","volume":"142","author":"Kurmi","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.112911_bib0090","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jpba.2017.09.029","article-title":"Stability behaviour of antiretroviral drugs and their combinations. 8: characterization and in silico toxicity prediction of degradation products of efavirenz","volume":"148","author":"Kurmi","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.112911_bib0095","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejpb.2019.06.018","article-title":"Stability behaviour of antiretroviral drugs and their combinations. 10: LC-HRMS, LC-MSn, LC-NMR and NMR characterization of fosamprenavir degradation products and in silico determination of their ADMET properties","volume":"142","author":"Singh","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jpba.2019.112911_bib0100","unstructured":"https:\/\/www.who.int\/hiv\/amds\/en\/Standard_Treatment_Guidelines-Final.pdf. (Accessed 22 September 2019)."},{"key":"10.1016\/j.jpba.2019.112911_bib0105","unstructured":"https:\/\/www.who.int\/hiv\/pub\/guidelines\/arv2013\/intro\/rag\/en\/index4.html. (Accessed 22 September 2019)."},{"key":"10.1016\/j.jpba.2019.112911_bib0110","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1016\/j.bmc.2014.04.018","article-title":"Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors","volume":"22","author":"Vanangamudi","year":"2014","journal-title":"Bioorganic. Med. Chem."},{"key":"10.1016\/j.jpba.2019.112911_bib0115","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/newbio233223b0","article-title":"Protein data bank","volume":"233","author":"Bank, Protein Data","year":"1971","journal-title":"Nature New Biol."},{"key":"10.1016\/j.jpba.2019.112911_bib0120","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpba.2019.112911_bib0125","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/acs.jctc.5b00864","article-title":"OPLS3: a force field providing broad coverage of drug-like small molecules and proteins","volume":"12","author":"Harder","year":"2015","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.jpba.2019.112911_bib0130","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1002\/jcc.21859","article-title":"Molecular modeling study of checkpoint kinase 1 inhibitors by multiple docking strategies and prime\/MM\u2013GBSA calculation","volume":"32","author":"Du","year":"2011","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.jpba.2019.112911_bib0135","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1023\/A:1025361621494","article-title":"In silico prediction of drug toxicity","volume":"17","author":"Dearden","year":"2003","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.jpba.2019.112911_bib0140","unstructured":"https:\/\/www.semanticscholar.org\/paper\/Development-and-Applications-of-Click-Chemistry-Patton\/bdde9f92bb49c2a1c23d2a6cb79fcbc564ce1ea6. (Accessed 25 December 2016)."},{"key":"10.1016\/j.jpba.2019.112911_bib0145","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nsmb.2223","article-title":"HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism","volume":"19","author":"Das","year":"2012","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.jpba.2019.112911_bib0150","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0969-2126(00)00513-X","article-title":"Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase","volume":"8","author":"Ren","year":"2000","journal-title":"Structure"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519314992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519314992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:58:33Z","timestamp":1760000313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708519314992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":30,"alternative-id":["S0731708519314992"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2019.112911","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stability behaviour of antiretroviral drugs and their combinations. 11: Characterization of interaction products of zidovudine and efavirenz, and evaluation of their anti HIV-1 activity, and physiochemical and ADMET properties","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2019.112911","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112911"}}